Healthpeak Properties DOC NYSE · Real estate · United States
$20.13 -1.25% -$0.26
Summary
54 / 100 · Bulios Score
What speaks for it
- Revenue grew by 11% a year over the last 3 years.
- The share price is below the Bulios Fair Price.
What to watch
- Earnings per share fell by 52% a year over the last 3 years.
- It cut its dividend by 57% last year.
- It earns only 2.4 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 35.8 USD for 1 USD of yearly profit. Over the last five years it was 62.8 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 11% a year over 5 years. Over the last 3 years it grew by 11% a year. Earnings per share fell by 52% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 97 USD
- Sales and administration -13 USD
- Taxes and other 3.6 USD
- Net profit 13 USD
Net profit, industry median (REIT - Healthcare Facilities) 15 USD
Out of every 100 USD of revenue, 13 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 29.1 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, at risk- Yield
- 6.06%
- Paid out of profit
- 217%
You receive $1.22 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Neutral- Buy 19
- Hold 22
- Sell 0
Today's price within the analysts' price targets
The average target of $22 is 9.3% above today's price. 46% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Outpatient Medical Buildings 47%
- Lab 31%
- Senior Housing 22%
By region
- Outpatient Medical Buildings 47%
- Lab 31%
- Senior Housing 22%
Outpatient Medical Buildings brings in 47% of revenue.
Segments in detail